A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2006
12/21/2006	US20060287227 Gonadal function improving agents
12/21/2006	US20060287223 Remodeling and glycoconjugation of peptides
12/21/2006	US20060286634 Vector
12/21/2006	US20060286150 Prevent menopause syndrome; therapy for skin aging; topical applying
12/21/2006	US20060286125 Immunomodulation; Yatapoxvirus polypeptide; multiple sclerosis, psoriasis, atopic dermatitis, type 1 insulin-dependent diabetes mellitus, dermatitis, Sjoigren's syndrome, encephalitis, Reiter's syndrome, psoriatic arthritis, progressive systemic sclerosis, primary biliary cirrhosis
12/21/2006	US20060286115 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule
12/21/2006	DE19843489B4 Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung Benzoylguanidine-derivatives having advantageous properties, to processes for their preparation and their use in the manufacture of medicinal products and pharmaceutical preparation containing them
12/21/2006	DE102005027556A1 New Raf kinase inhibitor peptide useful in the preparation of medicament for the treatment of tumor
12/21/2006	DE10061110B4 Expression der Keratingene 8 und 18 zur Therapie von Tumoren, insbesondere des Mammakarzinoms Expression of keratin genes 8 and 18 for the treatment of tumors, especially of breast cancer
12/21/2006	CA2612200A1 Method of cancer treatment using sirna silencing
12/21/2006	CA2611917A1 Injection
12/21/2006	CA2611893A1 Tetrahydroquinolines for use as modulators of the mitotic motor protein eg5
12/21/2006	CA2611892A1 Tetrahydroquinoline derivatives as motor protein eg5 inhibitors and antitumor agents
12/21/2006	CA2611865A1 N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof
12/21/2006	CA2611680A1 Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
12/21/2006	CA2611592A1 Liquid pharmaceutical formulations of docetaxel
12/21/2006	CA2611584A1 Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
12/21/2006	CA2611495A1 Aminopyrimidines as kinase modulators
12/21/2006	CA2611481A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
12/21/2006	CA2611470A1 Aminopyrimidines as kinase modulators
12/21/2006	CA2611263A1 Crystalline forms of a pyrrolotriazine compound
12/21/2006	CA2611242A1 Alkylquinoline and alkylquinazoline kinase modulators
12/21/2006	CA2611240A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
12/21/2006	CA2611204A1 Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines
12/21/2006	CA2597317A1 Uses of recombinant super-compound interferons
12/21/2006	CA2574090A1 Methods and compositions for inducing innate immune responses
12/20/2006	EP1734133A2 Heparanase specific molecular probes and their use in research and medical applications
12/20/2006	EP1734122A2 APO-2 ligand
12/20/2006	EP1734120A2 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
12/20/2006	EP1734064A2 Polymer guanidine derivatives as a cytostatic medicament
12/20/2006	EP1734053A2 Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
12/20/2006	EP1734051A2 Composition and methods for the diagnosis of tumours
12/20/2006	EP1734046A1 Radiosensitizer
12/20/2006	EP1734044A1 Process for producing folic acid derivative
12/20/2006	EP1733758A1 Methods for administration of a farnesyl dibenzodiazepinone
12/20/2006	EP1733743A1 Preventives/remedies for cancer
12/20/2006	EP1733740A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
12/20/2006	EP1733739A1 sFRP EXPRESSION POTENTIATING AGENT
12/20/2006	EP1733736A2 Method of producing recombinant antibodies against tumours
12/20/2006	EP1733735A2 Methods and products for inducing mucosal immunity
12/20/2006	EP1733728A2 Use of 2-alkoxyphenyl substituted imidazotriazinones as inhibitors of phosphodiesterase
12/20/2006	EP1733727A1 Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders
12/20/2006	EP1733726A1 Pharmaceutically active isoindoline derivatives
12/20/2006	EP1733237A2 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
12/20/2006	EP1733046A1 Combination therapies with epothilones and carboplatin
12/20/2006	EP1733036A2 Cancer prognosis and/or diagnosis method
12/20/2006	EP1732938A1 Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
12/20/2006	EP1732934A1 Novel thiazolopyrazoles and methods of their use
12/20/2006	EP1732926A1 Mitotic kinesin inhibitors
12/20/2006	EP1732920A2 Thiophene derivatives as chk 1 inhibitors
12/20/2006	EP1732919A1 Substituted thiophene derivatives as anti-cancer agents
12/20/2006	EP1732909A1 Water soluble esters of ¬n-(4-amino-2-butynyl)\| with anticancer activity
12/20/2006	EP1732905A1 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
12/20/2006	EP1732902A2 Nucleoside derivatives and therapeutic use thereof
12/20/2006	EP1732898A1 Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors
12/20/2006	EP1732897A1 Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions
12/20/2006	EP1732884A1 Sulphonamide derivatives
12/20/2006	EP1732650A1 Composition and method for cancer treatment
12/20/2006	EP1732603A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
12/20/2006	EP1732602A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
12/20/2006	EP1732601A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
12/20/2006	EP1732600A2 Uses of anti-ctla-4 antibodies
12/20/2006	EP1732599A1 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
12/20/2006	EP1732574A1 The use of o-atp for the treatment of diseases involving angiogenesis
12/20/2006	EP1732573A1 Biologically active compounds with anti-angiogenic properties
12/20/2006	EP1732569A1 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
12/20/2006	EP1732568A1 USES OF ERbeta MODULATORS
12/20/2006	EP1732554A2 Treatment regimen for camptothecin derivatives
12/20/2006	EP1732546A2 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
12/20/2006	EP1732543A2 Tetra-cyclic carboline deratives for inhibiting angiogenesis
12/20/2006	EP1732539A2 Use of beta-lapachone for the treatment of colon cancer
12/20/2006	EP1732536A2 Triptolide lactone ring derivatives as immunomodulators and anticancer agents
12/20/2006	EP1551822B1 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them
12/20/2006	EP1542977B1 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12.
12/20/2006	EP1506200B1 Diazabicyclic biaryl derivatives
12/20/2006	EP1456171B1 Substituted cyclohexane derivatives
12/20/2006	EP1441726B1 Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny]-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
12/20/2006	EP1438310B1 Beta-carbolin derivatives as ptp-inhibitors
12/20/2006	EP1434762B1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
12/20/2006	EP1401809B1 Tryptase inhibitors
12/20/2006	EP1390362B1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
12/20/2006	EP1357935B1 Reducing side effects of chemotherapy in cancer patients
12/20/2006	EP1357903B1 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY\|PHENOXY)-2-(4-METHOXYPHENYL) BENZO b\|THIOPHENE AND SALTS THEREOF
12/20/2006	EP1317537B1 G-csf analog compositions and methods
12/20/2006	EP1276720B1 2-acyl indol derivatives and their use as anti-tumour agents
12/20/2006	EP1272457B9 Compounds for modulating cell proliferation
12/20/2006	EP1256344B1 Remedies for endothelin-induced diseases
12/20/2006	EP1233058B1 Method of proliferating natural killer cells
12/20/2006	EP1187816B1 5-cyano-2-aminopyrimidine derivatives
12/20/2006	EP1172107B1 Drugs containing sulfopyranosylacylglycerol derivatives
12/20/2006	EP1135477B1 Humanized monoclonal integrin antibodies
12/20/2006	EP0836476B1 A COSMETIC COMPOSITION comprising the glycopropyl ester of retinoic acid FOR SKIN APPLICATIONS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF skin diseases, TUMOROUS CELLS, BLADDER OR NERVE DISORDERS
12/20/2006	EP0833660B1 Vectors for the diagnosis and treatment of solid tumors including melanoma
12/20/2006	CN1882610A High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
12/20/2006	CN1882602A The moduilation of hyaluronan synthesis and degradation in the treatment of disease
12/20/2006	CN1882586A 1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases
12/20/2006	CN1882580A Quinazoline derivatives as antiproliferative agents
12/20/2006	CN1882577A 喹唑啉衍生物 Quinazoline derivatives
12/20/2006	CN1882576A 喹唑啉衍生物 Quinazoline derivatives
12/20/2006	CN1882573A Quinazoline derivatives as tyrosine kinase inhibitors

1 ... 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 ... 2211